These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

945 related items for PubMed ID: 22006540

  • 21. ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.
    Rosenbaum-Krumme SJ, Görges R, Bockisch A, Binse I.
    Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1373-80. PubMed ID: 22718304
    [Abstract] [Full Text] [Related]

  • 22. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P, Kuhn-Lansoy C, Edet-Sanson A, Hapdey S, Modzelewski R, Hitzel A, d'Anjou J, Basuyau JP.
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [Abstract] [Full Text] [Related]

  • 23. 18F-FDG PET/CT and ultrasonogrpahy in differentiated thyroid carcinoma patients with elevated serum levels of antithyroglobulin antibody, negative Tg and whole body 131I scan.
    Liu J, Liu B, Yu Y, Chao F, Liu Y, Han X.
    Hell J Nucl Med; 2018 Jan; 21(1):24-27. PubMed ID: 29550843
    [Abstract] [Full Text] [Related]

  • 24. Effectiveness of [(124)I]-PET/CT and [(18)F]-FDG-PET/CT for localizing recurrence in patients with differentiated thyroid carcinoma.
    Lee J, Nah KY, Kim RM, Oh YJ, An YS, Yoon JK, An GI, Choi TH, Cheon GJ, Soh EY, Chung WY.
    J Korean Med Sci; 2012 Sep; 27(9):1019-26. PubMed ID: 22969247
    [Abstract] [Full Text] [Related]

  • 25. [F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan].
    Ruiz Franco-Baux JV, Borrego Dorado I, Gómez Camarero P, Rodríguez Rodríguez JR, Vázquez Albertino RJ, Navarro González E, Astorga Jiménez R.
    Rev Esp Med Nucl; 2005 Sep; 24(1):5-13. PubMed ID: 15701340
    [Abstract] [Full Text] [Related]

  • 26. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
    Finkelstein SE, Grigsby PW, Siegel BA, Dehdashti F, Moley JF, Hall BL.
    Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
    [Abstract] [Full Text] [Related]

  • 27. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels.
    Leboulleux S, El Bez I, Borget I, Elleuch M, Déandreis D, Al Ghuzlan A, Chougnet C, Bidault F, Mirghani H, Lumbroso J, Hartl D, Baudin E, Schlumberger M.
    Thyroid; 2012 Aug; 22(8):832-8. PubMed ID: 22853728
    [Abstract] [Full Text] [Related]

  • 28. Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas.
    Giovanella L, Ceriani L, De Palma D, Suriano S, Castellani M, Verburg FA.
    Head Neck; 2012 May; 34(5):626-31. PubMed ID: 21850699
    [Abstract] [Full Text] [Related]

  • 29. Utility of 8F-FDG PET/CT in well differentiated thyroid carcinoma with high serum antithyroglobulin antibody.
    Kingpetch K, Pipatrattana R, Tepmongkol S, Sirisalipoch S, Chaiwatanarat T.
    J Med Assoc Thai; 2011 Oct; 94(10):1238-44. PubMed ID: 22145510
    [Abstract] [Full Text] [Related]

  • 30. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
    Dennis K, Hay JH, Wilson DC.
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
    [Abstract] [Full Text] [Related]

  • 31. 68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG-Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin.
    Binse I, Poeppel TD, Ruhlmann M, Ezziddin S, Görges R, Sabet A, Beiderwellen K, Bockisch A, Rosenbaum-Krumme SJ.
    J Nucl Med; 2016 Oct; 57(10):1512-1517. PubMed ID: 27033897
    [Abstract] [Full Text] [Related]

  • 32. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
    Lee JW, Lee SM, Lee DH, Kim YJ.
    J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
    [Abstract] [Full Text] [Related]

  • 33. FDG-PET performed concurrently with initial I-131 ablation for differentiated thyroid cancer.
    Iwano S, Kato K, Ito S, Tsuchiya K, Naganawa S.
    Ann Nucl Med; 2012 Apr; 26(3):207-13. PubMed ID: 22160654
    [Abstract] [Full Text] [Related]

  • 34. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
    Rosario PW, Furtado Mde S, Mineiro Filho AF, Lacerda RX, Calsolari MR.
    Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
    [Abstract] [Full Text] [Related]

  • 35. Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan?
    Piccardo A, Foppiani L, Morbelli S, Bianchi P, Barbera F, Biscaldi E, Altrinetti V, Villavecchia G, Cabria M.
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):57-65. PubMed ID: 21285923
    [Abstract] [Full Text] [Related]

  • 36. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET.
    Freudenberg LS, Antoch G, Frilling A, Jentzen W, Rosenbaum SJ, Kühl H, Bockisch A, Görges R.
    Eur J Nucl Med Mol Imaging; 2008 May; 35(5):950-7. PubMed ID: 18193222
    [Abstract] [Full Text] [Related]

  • 37. The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan.
    Stangierski A, Kaznowski J, Wolinski K, Jodlowska E, Michaliszyn P, Kubiak K, Czepczynski R, Ruchala M.
    Nucl Med Commun; 2016 Sep; 37(9):935-8. PubMed ID: 27383190
    [Abstract] [Full Text] [Related]

  • 38. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
    Kim MH, O JH, Ko SH, Bae JS, Lim DJ, Kim SH, Baek KH, Lee JM, Kang MI, Cha BY, Lee KW.
    Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
    [Abstract] [Full Text] [Related]

  • 39. [Diagnostic accuracy of 18F-FDG PET in residual or recurrent differentiated thyroid carcinoma with high thyroglobulin and negative 131-I whole-body scan].
    Cabrera Martín MN, Pasamontes Pingarrón JA, Carreras Delgado JL, Lapeña Gutiérrez L, Delgado Bolton RC, Bittini Copano A, Pérez Castejón MJ, Fernández Pérez C.
    Rev Esp Med Nucl; 2007 Feb; 26(5):263-9. PubMed ID: 17910834
    [Abstract] [Full Text] [Related]

  • 40. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.
    Muros MA, Llamas-Elvira JM, Ramírez-Navarro A, Gómez MJ, Rodríguez-Fernández A, Muros T, López de la Torre M, Becerra A, Carreras JL.
    Am J Surg; 2000 Jun; 179(6):457-61. PubMed ID: 11004330
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 48.